Menu Back to DIA-Asia-2021

Overview

The COVID-19 outbreak brought unprecedented changes to the way we live and work, especially in the R&D field. DIA Asia 2021 will be the first transnational post-COVID conference connecting industry experts and regulators to discuss key learnings and takeaways in the clinical trial and regulatory space across the Asia region. Current learnings will create a post-pandemic view on the new regulatory landscape, innovative virtual trials, Real-World Evidence and the potential implications to accelerate drug development.

Join this multi-stakeholder, neutral forum to:

  • Explore new technology adoptions in revolutionizing healthcare for better diagnostics and patient outcomes.
  • Receive updates on regulatory processes, policies, innovative drug review pathways, software regulations and adoption of virtual inspections.
  • Learn how clinical trials are taking a more patient centric approach and get updated on the implementation of remote monitoring in Asia and the challenges that arise.
  • Understand the regulations surrounding nutraceuticals/nutrition and their role in today’s healthcare.

Why you should attend:

  • This is the very first time that DIA is hosting a transnational conference in the Asia region.
  • The meeting provides a unique forum to gain a holistic view on the clinical trial and regulatory space post-COVID evolution.
  • Join this virtual meeting from all over the world to learn about the latest developments in the Asia region.

This meeting is the ideal place for:

  • Industry professionals in Pharmaceuticals and Medical Technologies involved in Research & Development, Regulatory Affairs, and Medical Affairs.
  • Regulators and personnel from Health Authorities and Ministries.
  • Patient and Patient Support Groups.
  • Experts from Academia and Research

Program Committee

  • Shun  Jin, MBA
    Shun Jin, MBA Head, Regulatory Affairs, APMA
    Sandoz Asia Pacific Pharmaceutical Pte., Ltd., Singapore
  • Jing Ping  Yeo, PhD
    Jing Ping Yeo, PhD Vice President- Asia Pacific head
    Cytel International , Singapore
  • Kum Cheun  Wong, PharmD
    Kum Cheun Wong, PharmD Head Asia Pacific Regulatory & Development Policy
    Novartis Asia Pacific Pharmaceuticals Pte. Ltd., Singapore
  • Vicky (Fengyun)  Han
    Vicky (Fengyun) Han Senior Director, Asia Pacific Regulatory Policy Group Lead, Asia Pacific
    Johnson & Johnson Pte. Ltd., Singapore
  • Jessica  Liu, MD
    Jessica Liu, MD Vice President, Head of International Business
    Tigermed Consulting Co., Ltd, China
  • Ling  Su, PhD
    Ling Su, PhD Professor
    Shenyang Pharmaceutical University, China
  • Rie  Matsui, RPh
    Rie Matsui, RPh Senior Director, Regional Labeling Head for APAC
    Pfizer R&D Japan G.K., Japan
  • Junko  Sato, PhD
    Junko Sato, PhD Director, Office of International Programs
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Hideki  Maeda, PhD
    Hideki Maeda, PhD Professor, Department of Regulatory Science
    Meiji Pharmaceutical University, Japan
  • Shinichi  Nishiuma, MD
    Shinichi Nishiuma, MD Head of Oncology Medical Science, Japan medical
    Bristol-Myers Squibb K.K., Japan
Load More

Contact us

Registration Questions?


Send Email
+91 9029098844


Digital Learning Catalog

DIA Learning: eLearning Soultions
Download